Explore the Agenda
7:00 am Check In, Morning Coffee & Light Refreshments
7:55 am Chair’s Opening Remarks
Striving for the Next Wave of ADC Innovation: Contextualizing Novel ADC Mechanism & Design Validation to De-Risk Future ADC Development & Deliver Differentiated Patient Benefit
8:00 am Panel Discussion: Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact
- Evaluating the landscape of ADC therapies one year on: Is the field pursuing the right amount of innovation to secure the next wave of ADCs beyond Topo1?
- Delving into payload mechanisms and non-traditional ADC design: What avenues of innovation are showing promise and what needs to be demonstrated?
- Assessing hurdles and opportunities to achieve differentiated ADC clinical profiles and patient impact in crowded oncology indications
- Peering into the crystal ball: Debating the future direction of the ADC field and pioneering future possibilities
9:00 am WuXiDARx™ Conjugation Technology & Proprietary Payload-Linker Platform: A Powerful Alliance for Next-Generation Dual Payload ADC Development
- Advancing next-generation dual-payload ADCs to address traditional challenges like drug resistance and narrow therapeutic windows
- Leveraging WuXiDARx™ technology for flexible DAR1-6 and WuXiTecan2™ hydrophilic linker, enabling streamlined dual-payload construction without antibody engineering
- Demonstrating a substantially wider therapeutic index alongside significantly enhanced anti-tumor efficacy in proof-of-concept studies
9:30 am Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Understand How Enhanced Design & Preclinical Characterization Links to Differentiated ADC Clinical Performance
- Laying out the development and vision of STRO-004 leveraging enhanced antibody engineering and linker-payload design to translate into impactful clinical performance against existing ADC therapies
- Exploring brand-new Phase I clinical safety and PK data targeting Tissue Factor, contextualized with how well STRO-004 translated from cyno monkey preclinical data, to understand ADC clinical benefit and enhanced therapeutic index
- Highlighting rationale, development and the power of dual payload ADCs to subvert patient resistance mechanisms to single payload ADCs
10:00 am Morning Break & Structured Networking
Discovery Chemistry
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery Chemistry
Leveraging Novel Payload Mechanisms & Combinations to Combat Topo1 & MMAE Patient Resistance
Theme 1: Striving for Innovative Payload Mechanisms to Advance Beyond the Topo1 Dogma
Presentation Preview: PROTAC ADCs: Incorporating Historical Learnings to Navigate Novel Payload Development Beyond Blind Potency
Associate Director, Medicinal Chemistry, AstraZeneca
- Highlighting rationale for developing the first reported degrader payloads versus a known oncology target in light of lack of efficacy from small molecule inhibitors
- Laying out medicinal chemistry approaches to optimize PROTAC payload properties and exploring variety of conjugation approaches
- Showcasing potent data generated in preclinical models and highlighting next steps in novel payload development
4 sessions
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
1:00 pm Lunch & Networking
Discovery Chemistry
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery Chemistry
Theme 2: Employing Rationale- Driven Dual Payload Combinations to Circumvent Validated Payload Resistance
Presentation Preview: Harnessing the Promise of Dual Payload ADCs to Combat Resistance to Traditional ADCs
Chief Scientific Officer, Callio Therapeutics
- Designing multi-mechanism, complementary dual payload ADCs to drive deep and durable responses across a broad range of solid tumors
- Pioneering the next generation of dual payload ADCs featuring rationally selected payload combinations designed to overcome treatment resistance to single-payload ADCs
- Contextualizing lead dual payload ADC, CLIO-8221, currently in clinical trials, with a second program expected to enter the clinic in late 2026
4 sessions
Discovery Biology
Preclinical
Translational Medicine
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
4:00 pm Afternoon Break & Scientific Poster Showcase
Demonstrating the Transformative Impact of ADCs to Reshape the Standard of Oncology Care & Deliver Improved Therapeutic Outcomes for Patients in Early-Line Settings
5:00 pm Evaluating I-SPY2 Clinical Data & Toxicity Monitoring to Assess ADC Progression to Early-Stage Oncology Settings in TNBC & HER2+ Breast Cancer
- Contextualizing I-SPY2 trials evaluating progression of ADCs to neoadjuvant and adjuvant settings in TNBC & HER2+ breast cancer
- Laying out clinical data generated to investigate early-line ADC progression, including recent clinical performance of Enhertu and Datroway
- Evaluating concerns with ADC-associated side effects, focusing on ILD monitoring, when considering advancement to neoadjuvant settings
5:30 pm Expansion of ADC R&D & Manufacturing Capabilities in a Payload-Linker CDMO
- Navigating buildout of ADC clinical manufacturing for diverse, highly potent payloads
- Exploring implementation of bioconjugation and bioanalytical capabilities within R&D
- Leveraging process and analytical characterization insights from commercial ADCs
6:00 pm Setting the Scene for Novel Combination Partner Approaches for Vedotin-Based ADCs Including PADCEV
- Contextualizing the significance of combination approaches within the future of ADC patient impact in early-line oncology therapies
- Laying out the transformative clinical performance of Padcev-Keyruda combination including event free survival in MIBC
- Addressing the need and opportunity for novel combinations partners to enhance Padcev clinical impact
6:30 pm Chair’s Closing Remarks
6:30 pm Evening Drinks Reception
Enjoy an informal end to the busiest conference day. With a backdrop of palm trees and the San Diego sunset, savor a drink of your choice, reconnect with peers, and meet fresh faces to break down your ADC learnings and objectives.